Dynamic illusory waves generated by relative motion in periodic displays.

Pancreatic neuroendocrine tumours (NETs) are rare and account for less than two per cent of all pancreatic cancers []. These well-differentiated neoplasms arise from pancreatic islet cells and are classified according to their proliferation rate into low-, intermediate-, and high-grade tumours [,]. Most pancreatic NETs are non-functional, and their clinical presentation depends on both the extent of the primary tumour and the presence of distant metastases []. Pancreatic NETs typically overexpress somatostatin receptors (SSRs) on the tumour cell surface, which can be detected using SSR-based functional imaging. SSR negativity on SSR-directed imaging studies is associated with less differentiated NETs, more aggressive biological behaviour, and limited eligibility for SSR-targeted therapies []. Pancreatic NETs have a worse prognosis than NETs arising from other primary sites []. In recent years, several therapeutic options have been approved for the treatment of metastatic pancreatic NETs (including somatostatin analogues, targeted therapies such as everolimus and sunitinib, peptide receptor radionuclide therapy, and chemotherapy), contributing to improved overall survival. However, evidence regarding the optimal sequencing of these treatments remains limited [].